Dennis Ford of Life Science Nation shared tips on interacting with investors as you work on a strategic method of fundraising for your R&D.

View Slide Deck

John Nobile of Tangen Biosciences talked about his company’s process in achieving their recent contract with BARDA.


Dr. Joe Larsen of the Biomedical Advanced Research and Development Authority discussed current CBRN threats and BARDA’s role in developing and stockpiling countermeasures.

View Slide Deck

Dr. Natalie Wisniewski, of Profusa, Inc., gave some insight about her company’s non-dilutive funding journey, starting with their initial grant from DARPA in 2011 through to today.


Dr. James B. Phillips of USAMRMC, Department of Defense, shared with the audience the mission of the US Army Medical Research and Material Command and the Medical Technology Enterprise Consortium, discussing opportunities available for partnering and engaging with Industry.

View Slide Deck

Ram May-Ron, Managing Partner of the FreeMind Group, opened the 13th Annual Non-Dilutive Funding Summit with a few comments on the value of non-dilutive funding to the life sciences industry.

Ram May-Ron of the FreeMind Group opens the 12th Annual Non-Dilutive Funding Summit with a few remarks on recent trends in life science R&D funding and the importance of federal grants as a strategic source of funds.

Dr. Ronald Hann of the Defense Threat Reduction Agency (DTRA) presents the keynote address on Preparing for the Unthinkable.

 

View Slide Deck

Tyler Merkeley of the Biomedical Advanced Research and Development Authority (BARDA) CARB-X program talks about the novel non-dilutive partnership created to promote innovation and foster a robust antimicrobials pipeline.

 

View Slide Deck

Paul McQuade of Greenberg Traurig, LLP shares some legal aspects of federal technology investment and their potential impact on intended markets.

 

View Slide Deck